The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis

Journal of Clinical Gastroenterology

Volumn 46, Issue 2, 2012, Pages 155-161

  Wong, Robert John ^a   Gish, Robert ^b   Frederick, Todd ^a   Bzowej, Natalie ^a   Frenette, Catherine ^c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Asians and Hispanics; autoimmune hepatitis epidemiology; race ethnic disparities

Indexed keywords

ALBUMIN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ASIAN; AUTOIMMUNE HEPATITIS; COHORT ANALYSIS; ETHNICITY; FEMALE; HISPANIC; HUMAN; HUMAN TISSUE; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; ASIAN AMERICANS; CHRONIC DISEASE; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HEPATITIS, AUTOIMMUNE; HISPANIC AMERICANS; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREVALENCE; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84855800153     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318228b781     Document Type: Article

References (37)

1. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51: 2193-2223.
2. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol. 2001;96:1224-1231. (Pubitemid 32319165)
3. Czaja AJ. Drug therapy in management of type 1 autoimmune hepatitis. Drugs. 1999;57:49-68. (Pubitemid 29042015)
4. Czaja AJ. Features reflective of early prognosis in corticosteroid- treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95:448-453.
5. Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology. 1991;13:701-706.
6. Strettell MDJ, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology. 1997;112:2028-2203.
7. Czaja AJ, Strettell MDJ, Thomson LJ, et al. Associations etween alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology. 1997;25: 317-323. (Pubitemid 27069049)
8. Czaja AJ, Carpenter HA, Santrach PJ, et al. Significance of HLA DR4 in type 1 autoimmune hepatitis. Gastroenterology. 1993;105:1502-1507. (Pubitemid 23315327)
9. Seki T, Kiyosawa D, Inoko H, et al. Association of autoimmune hepatitis with HLA-Bw54 and DR4 in Japanese patients. Hepatology. 1990;12:1300-1303.
10. Seki T, Ota M, Furuta S, et al. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology. 1992;103:1041-1047.
11. Zolfino T, Heneghan MA, Norris S, et al. Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin. Gut. 2002;50:713-717. (Pubitemid 34407503)
12. Czaja AJ, Souto EO, Bittencourt PL, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol. 2002;37:302-308. (Pubitemid 34969945)
13. Qiu DK, Ma X. Relationship between human leukocyte antigen-DRB1 and autoimmune hepatitis type I in Chinese patients. J Gastroenterol Hepatol. 2003;18:63-67. (Pubitemid 36062589)
14. Hurlburt KJ, McMahon BJ, Deubner H, et al. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002;97:2402-2407.
15. Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007;46:1828-1835.
16. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999;31:929-938. (Pubitemid 29514229)
17. Silva IS, eds. Cancer Epidemiology: Principles and Methods. Geneva, Switzerland: World Health Organization; 1999.
18. Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology. 2009;50:291-308.
19. Manns MP, Kruger M. Immunogenetics of chronic liver diseases. Gastroenterology. 1994;106:1676-1697. (Pubitemid 24163143)
20. Lim KN, Casanova RL, Boyer TD, et al. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol. 2001;96:3390-3394. (Pubitemid 34016665)
21. Nguyen GC, Thuluvath PJ. Racial disparity in liver disease: biological, cultural, or socioeconomic factors. Hepatology. 2008;47:1058-1066. (Pubitemid 351449697)
22. Mchutchinson L, Poynard T, Pianko S, et al. The impact of interferon plus ribivirin on response to therapy in blacks with chronic hepatitis C. Gastroenterology. 2000;119:1317-1323.
23. Park IU, Taylor AL. Race and ethnicity in trials of antihypertensive therapy to prevent cardiovascular outcomes: a systematic review. Ann Fam Med. 2007;5:444-452. (Pubitemid 47535976)
24. The ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002;228:2891-2897.
25. Wong RJ, Corley DA. Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States. Dig Dis Sci. 2009;54:2031-2039.
26. Powers DR, Wallin D. End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy. Arch Intern Med. 1998;158:793-800. (Pubitemid 28204665)
27. Devlin JJ, O'Grady JG, Tan KC, et al. Ethnic variations in patient and graft survival after liver transplantation: identification of a new risk factor for chronic allograft rejection. Transplantation. 1993;56:1381-1384. (Pubitemid 24018790)
28. Neylan JF. For the FK506 Kidney Transplant Study Group: racial differences in renal transplantation after immunosuppression with tracrolimus versus cyclosporine. Transplantation. 1998;65:515-523.
29. Fitzsimmons WE, Bekersky I, Dressler D, et al. Demographic considerations in tacrolimus pharmacokinetics. Transplant Proc. 1998;30:1359-1364. (Pubitemid 28309604)
30. Fleckenstein J. Chronic hepatitis C in African Americans and other minority groups. Curr Gastroenterol Rep. 2004;6:66-70. (Pubitemid 39359587)
31. Wong RJ. Marked variations in colon cancer epidemiology: sex-specific and race/ethnicity-specific disparities. Gastroenterol Res. 2009;2:268-276.
32. Petri M. The effect of race on the incidence and clinical course in systemic lupus erythematosus: the Hopkins lupus cohort. J Am Med Womens Assoc. 1998;53:9-12.
33. Tull ES, Barinas E. A two-fold excess mortality among black compared with white IDDM patients in Allecheny county, Pennsylvania: Pittsburgh DERI Mortality Study Group. Diabetes Care. 1996;19:1344-1347. (Pubitemid 26418612)
34. Fortes Mdel P, Machado IW, Gil G, et al. Genetic contribution of major histocompatibility complex class II region to type 1 autoimmune hepatitis susceptibility in Venezuela. Liver Int. 2007;27:1409-1416. (Pubitemid 350142256)
35. Qiu DK, Ma X. Relationship between human leukocyte antigen-DRB1 and autoimmune hepatitis type I in Chinese patients. J Gastroenterol Hepatol. 2003;18:63-67. (Pubitemid 36062589)
36. Vá zquez-Garciacute;a MN, Alá ez C, Olivo A, et al. MHC class II sequences of susceptibility and protection in Mexicans with autoimmune hepatitis. J Hepatol. 1998;28:985-990. (Pubitemid 28275977)
37. U.S. Census Bureau. Census Bureau Estimates Nearly Half of Children Under Age 5 are Minorities. Available at: http:// www.census.gov/newsroom/releases/ archives/population/cb09- 75.html. Accessed June 25, 2010.